Clavulanic acid inhibits MPP+-induced ROS generation and subsequent loss of dopaminergic cells

Brain Research

Volumn 1469, Issue , 2012, Pages 129-135

  Kost, Gina Chun ^a   Selvaraj, Senthil ^b   Lee, Young Bok ^a   Kim, Deog Joong ^a   Ahn, Chang Ho ^a   Singh, Brij B ^b  

^a Rexahn Pharmaceuticals Inc   (United States)

^b UNIVERSITY OF NORTH DAKOTA SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

Apoptosis; Clavulanic acid; Mitochondria; MPTP; Neuroprotection; Parkinson's disease (PD)

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; CASPASE; CLAVULANIC ACID; CYTOCHROME C; PROTEIN BAX; PROTEIN BCL XL; REACTIVE OXYGEN METABOLITE;

ANIMAL CELL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG INHIBITION; MITOCHONDRIAL MEMBRANE POTENTIAL; MOTOR PERFORMANCE; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL;

1-METHYL-4-PHENYLPYRIDINIUM; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CASPASE 3; CASPASE 9; CELL LINE, TUMOR; CLAVULANIC ACID; CYTOCHROMES C; DOPAMINE; HUMANS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOCHONDRIA; NEURONS; NEUROPROTECTIVE AGENTS; REACTIVE OXYGEN SPECIES;

ANIMALIA;

EID: 84864756380     PISSN: 00068993     EISSN: 18726240     Source Type: Journal    
DOI: 10.1016/j.brainres.2012.06.005     Document Type: Article

References (26)

1. H. Ammer, and R. Schulz Retinoic acid-induced differentiation of human neuroblastoma SH-SY5Y cells is associated with changes in the abundance of G proteins J. Neurochem. 62 April 4 1994 1310 1318 (Pubitemid 24098078)
2. B. Antonsson, F. Conti, A. Ciavatta, S. Montessuit, S. Lewis, I. Martinou, L. Bernasconi, A. Bernard, J.J. Mermod, G. Mazzei, K. Maundrell, F. Gambale, R. Sadoul, and J.C. Martinou Inhibition of Bax channel-forming activity by Bcl-2 Science 277 1997 370 372 (Pubitemid 27450709)
3. I. Budihardjo, H. Oliver, M. Lutter, X. Luo, and X. Wang Biochemical pathways of caspase activation during apoptosis Annu. Rev. Cell Dev. Biol. 15 1999 269 290 (Pubitemid 32250377)
4. R.E. Burke Programmed cell death and Parkinson's disease Mov. Disord. 13 Suppl. 1 1998 17 23
5. R.S. Burns, C.C. Chiueh, S.P. Markey, M.H. Ebert, D.M. Jacobowitz, and I.J. Kopin A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Proc. Natl. Acad. Sci. USA 80 1983 4546 4550 (Pubitemid 13077876)
6. S. Desagher, and J.C. Martinou Mitochondria as the central control point of apoptosis Trends Cell Biol. 10 2000 369 377 (Pubitemid 30612469)
7. E.R. Dorsey, R. Constantinescu, J.P. Thompson, K.M. Biglan, R.G. Holloway, K. Kieburtz, F.J. Marshall, B.M. Ravina, G. Schifitto, A. Siderowf, and C.M. Tanner Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030 Neurology 68 2007 384 386 (Pubitemid 46184217)
8. E. Ferreiro, C.R. Oliveira, and C.M.F. Pereira The release of calcium from the endoplasmic reticulum induced by amyloid-beta and prion peptides activates the mitochondrial apoptotic pathway Neurobiol. Dis. 30 2008 331 342
9. Y. Huh, M.S. Ju, H. Park, S. Han, Y.-M. Bang, C.F. Ferris, G.A. Koppell, J.A. King, M.L. Kim, D.J. Kim, C.H. Ahn, and M.-S. Oh Clavulanic acid protects neurons in pharmacological models of neurodegenerative diseases Drug Develop. Res. 71 2010 351 357
10. J.A. Javitch, R.J. D'Amato, S.M. Strittmatter, and S.H. Snyder Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity Proc. Natl. Acad. Sci. USA 82 1985 2173 2177 (Pubitemid 15056491)
11. D.J. Kim, J.A. King, L. Zuccarelli, C.F. Ferris, G.A. Koppel, CT Snowdon, and CH Ahn Clavulanic acid: a competitive inhibitor of beta-lactamases with novel anxiolytic-like activity and minimal side effects Pharmacol. Biochem. Behav. 93 2 2009 112 120
12. G. Kroemer, and J.C. Reed Mitochondrial control of cell death Nat. Med. 6 5 2000 513 519 (Pubitemid 30305900)
13. J.W. Langston, and I. Irwin MPTP: current concepts and controversies Clin. Neuropharmacol. 9 1986 485 507 (Pubitemid 17217320)
14. C.P. LeBel, H. Ischiropoulos, and S.C. Bondy Evaluation of the probe 2′,7′- dichlorofluorecein as a indicator of reactive oxygen species formation and oxidative stress Chem. Res. Toxicol. 5 1992 227 231
15. M. Lohle, and H. Reichmann Clinical neuroprotection inParkinson's disease - still waiting for the breakthrough J. Neurol. Sci. 289 2010 104 114
16. P. Marchetti, D. Decaudin, A. Macho, N. Zamzami, T. Hirsch, S.A. Susin, and G. Kroemer Redox regulation of apoptosis: impact of thiol oxidation status on mitochondrial function. Eur. J. Immunol. 27 1 1997 289 296 (Pubitemid 27046090)
17. H. Nakagawa, M. Yamada, K. Tokiyoshi, Y. Miyawaki, and T. Kanayama Penetration of potassium clavulanate/ticarcillin sodium into cerebrospinalfluid in neurosurgical patients Jpn. J. Antibiot. 47 1994 93 101 (Pubitemid 24057778)
18. D.J. Payne, R. Cramp, D.J. Winstanley, and D.J. Knowles Comparative activities of clavulanic acid, sulbactam, and tazobactam against clinically important beta-lactamases Anti-microb. Agents Chemother. 38 1994 767 772 (Pubitemid 24114016)
19. A. Samii, J.G. Nutt, and B.R. Ransom Parkinson's disease Lancet 363 2004 1783 1793 (Pubitemid 38698383)
20. A. Schober Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP Cell Tissue Res. 318 2004 215 224 (Pubitemid 39366054)
21. S. Selvaraj, J.A. Watt, and B.B. Singh TRPC1 inhibits apoptotic cell degeneration induced by dopaminergic neurotoxin MPTP/MPP() Cell Calcium. 46 September 3 2009 209 218
22. R.J. Smeyne, and V. Jackson-Lewis The MPTP model of Parkinson's disease Brain Res. Mol. Brain Res. 134 2005 57 66 (Pubitemid 40409495)
23. P.K. Sonsalla, and R.E. Heikkila The influence of dose and dosing interval on MPTP-induced dopaminergic neurotoxicity in mice Eur. J. Pharmacol. 129 1986 339 345 (Pubitemid 16008029)
24. S.A. Susin, N. Zamzami, and G. Kroemer Biochim. Biophys. Acta 1366 1998 151 165
25. S. Tan, Y. Sagara, Y. Liu, P. Mather, and D. Schubert J. Cell Biol. 141 1998 1423 1432
26. T. Voss, and B. Ravina Neuroprotection in Parkinson's disease:myth or reality? Curr. Neurol. Neuro. Sci. Rep. 8 2008 304 309